<DOC>
	<DOCNO>NCT00428090</DOCNO>
	<brief_summary>Rosiglitazone ( RSG ) test approved treatment type II diabetes mellitus , disease occur body ineffectively use glucose . RSG XR , investigational drug , extended-release form RSG . This study test whether RSG XR safely provide benefit people mild moderate Alzheimer 's disease ( AD ) . RSG XR new approach AD therapy study test whether one 's gene alter effectiveness RSG XR . Glucose use cell make energy need live . Changes ability cell use glucose lead disease like diabetes . Glucose level may lower brain AD patient , brain cell may also use glucose less well unaffected people . The proper function brain cell may critical memory think . If brain cell use glucose poorly , might impact AD . Drugs help brain cell properly use glucose may help person maintain normal memory thinking . Data suggest RSG may help AD patient first see small study Univ . Washington large international GSK study . In first study , receive RSG daily 6 month score well 3 test memory think receive RSG . In GSK study , benefit therapy RSG XR specific genetic pattern . They lack gene cause produce apolipoprotein E e4 ( APOE e4 ) . Subjects APOE e4 gene may two copy , one parent , may one APOE e4 gene meaning inherit either APOE e2 APOE e3 version gene one parent . Subjects one copy APOE e4 gene remain fairly stable two copy APOE e4 continue worsen 6-month treatment . This study directly test effect RSG XR people either lack APOE e4 gene .</brief_summary>
	<brief_title>Rosiglitazone ( Extended Release Tablets ) As Monotherapy In Subjects With Mild To Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>A 24-week , double-blind , double-dummy , randomize , parallel-group study investigate effect rosiglitazone ( extended release tablet ) , donepezil , placebo monotherapy cognition overall clinical response APOE e4-stratified subject mild moderate Alzheimer 's disease . ( REFLECT-1 )</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Inclusion criterion : Clinical diagnosis probable Alzheimer 's Disease ( AD ) . MMSE score 10 23 Has take approve AD therapy last 30 day . No previous hypersensitivity/intolerance AChEIs Have regular caregiver . Exclusion criterion : Diagnosis vascular dementia . Type I secondary diabetes mellitus . Type II diabetes mellitus treat insulin , sulfonylurea glipizide . History evidence congestive heart failure , clinically significant peripheral edema anemia . History significant psychiatric illness , major depressive disorder current depression need initiation treatment .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>apolipoprotein E</keyword>
	<keyword>monotherapy</keyword>
	<keyword>cognition</keyword>
	<keyword>mild</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>moderate</keyword>
</DOC>